Menu
LAUSANNE, Switzerland - 06 October 2016 – Sophia Genetics, the global leader in Data-Driven Medicine (DDM), today introduced ONCOPORTAL. This new technology digitally matches the unique genomic profile of patient tumours with actionable information on the best available treatments, cancer aggressiveness and relevant ongoing clinical trials. Accessible through the V4.0 of Sophia DDM®, ONCOPORTAL dramatically improves the diagnosis and treatment of solid tumours and haematological malignancies for patients around the world.
Powered by SOPHiA, the most advanced artificial intelligence in Data-Driven Medicine, Sophia DDM® is already being used by 180 leading hospitals in 31 countries to analyse genomics data produced on next generation DNA sequencers. The AI accurately detects and characterises patient-specific alterations for 70 genomic test applications, helping to better diagnose 200 patients daily.
With ONCOPORTAL, Sophia DDM® users now not only detect patient-specific alterations with top analytical performance, but also benefit from actionable information associated with it. In just a few clicks, pathologists and oncologists can access a comprehensive and easy to read report comprising diagnostic and prognosis information about patient tumours, lists of the best associated treatments, the efficacy of relevant drugs, toxicity and adverse events.
When no drugs match a patient’s tumour, the concise actionable report generated on ONCOPORTAL provides easy to consult information about ongoing clinical trials from phase I, II, III and IV corresponding to the tumour’s genomic profile. For patients, this presents new care options that match their unique tumour profile and timely access to the most promising therapeutic options.
Until recently, pathologists and oncologists had to spend precious time sequencing patient tumours genomic profiles. They had to bioinformatically analyse the data to detect genomic alterations and finally undertake a laborious process to identify treatments – with virtually no guarantee that the treatments would fit the patient unique genomic profile. Thanks to ONCOPORTAL, pathologists and oncologists can now access a comprehensive report with all this information in one place and in a standardised and integrated manner just a couple of hours after uploading the raw genomic data on Sophia DDM®.
As users add information and share knowledge on the Sophia DDM® platform, ONCOPORTAL is constantly updated with the latest medical knowledge thanks to machine learning techniques, allowing clinicians to save time and focus on the most complex cases.
Dr Pierre Hutter, CSO and Co-founder at Sophia Genetics said “Tumours result first and foremost from genomic alterations, which cause cells to go awry. In cancer care, therapeutic decisions do not rely solely on morphology anymore, but also on the unique molecular profile of a patient’s tumour. The technology introduced today addresses this challenge by providing pathologists and oncologists with actionable information that helps them accelerate their fight against cancer.”
Jurgi Camblong CEO and Co-founder at Sophia Genetics explained “We use SOPHiA to gather all the information oncologists need in a comprehensive yet concise report. By scanning through an enormous amount of genomic data and the collective knowledge contributed to Sophia DDM®, ONCOPORTAL gives clinicians precious information about their patient tumours and the broadest treatment options available.”
Jurgi Camblong concluded, “With the ever-increasing number of tumours analysed by SOPHiA every day and an average of 10 new hospitals joining every month, we will very soon be in a position to move to real-time epidemiology – which means that we will, for example, be able to say that the cancer of patient X looks like the cancer of 10,000 other patients, among whom 10% received treatment Y and survived. By enabling the democratisation of Data-Driven Medicine, SOPHiA is a real game changer in the fight against cancer.” .
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
